JP2016521684A - 安定化次亜塩素酸溶液及びその使用 - Google Patents
安定化次亜塩素酸溶液及びその使用 Download PDFInfo
- Publication number
- JP2016521684A JP2016521684A JP2016515094A JP2016515094A JP2016521684A JP 2016521684 A JP2016521684 A JP 2016521684A JP 2016515094 A JP2016515094 A JP 2016515094A JP 2016515094 A JP2016515094 A JP 2016515094A JP 2016521684 A JP2016521684 A JP 2016521684A
- Authority
- JP
- Japan
- Prior art keywords
- solution
- divalent cation
- hypochlorous acid
- magnesium
- amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000000845 anti-microbial effect Effects 0.000 claims abstract description 66
- -1 phosphate anion Chemical class 0.000 claims abstract description 50
- 230000008569 process Effects 0.000 claims abstract description 50
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 41
- 150000001768 cations Chemical class 0.000 claims abstract description 41
- 239000010452 phosphate Substances 0.000 claims abstract description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000004599 antimicrobial Substances 0.000 claims abstract description 20
- 208000015181 infectious disease Diseases 0.000 claims abstract description 15
- 238000012084 abdominal surgery Methods 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 9
- 239000000243 solution Substances 0.000 claims description 163
- 239000000203 mixture Substances 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 18
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 18
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 14
- 239000011777 magnesium Substances 0.000 claims description 14
- 229910052749 magnesium Inorganic materials 0.000 claims description 14
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 12
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 11
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 11
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 11
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 9
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 9
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 8
- 239000003002 pH adjusting agent Substances 0.000 claims description 6
- 208000029836 Inguinal Hernia Diseases 0.000 claims description 5
- 238000002357 laparoscopic surgery Methods 0.000 claims description 5
- 238000002350 laparotomy Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 108010059993 Vancomycin Proteins 0.000 claims description 4
- 238000007486 appendectomy Methods 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims description 4
- 229960003165 vancomycin Drugs 0.000 claims description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 4
- 241000222122 Candida albicans Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000588770 Proteus mirabilis Species 0.000 claims description 3
- 241000607715 Serratia marcescens Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000219470 Mirabilis Species 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 description 14
- 150000003839 salts Chemical class 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 12
- 244000005700 microbiome Species 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 210000000683 abdominal cavity Anatomy 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000003200 peritoneal cavity Anatomy 0.000 description 6
- 230000003139 buffering effect Effects 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 4
- 108010013639 Peptidoglycan Proteins 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 230000003187 abdominal effect Effects 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 229920006008 lipopolysaccharide Polymers 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000031729 Bacteremia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000037487 Endotoxemia Diseases 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005868 electrolysis reaction Methods 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 239000005020 polyethylene terephthalate Substances 0.000 description 3
- 229920000139 polyethylene terephthalate Polymers 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000004797 therapeutic response Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000007375 bacterial translocation Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Chemical compound Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229920001684 low density polyethylene Polymers 0.000 description 2
- 239000004702 low-density polyethylene Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229920010126 Linear Low Density Polyethylene (LLDPE) Polymers 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000011358 absorbing material Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000013626 chemical specie Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002192 cholecystectomy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001925 cycloalkenes Chemical class 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000005202 decontamination Methods 0.000 description 1
- 230000003588 decontaminative effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Engineering & Computer Science (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Agronomy & Crop Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
腹部手術を受けたヒト患者では、通常は腸に存在するグラム陽性菌及び/又はグラム陰性菌が、腸壁を通過し循環へと達し得る。手術の間及び/又は手術の前には、絶食や虚血などの状態が存在し得、これによりバクテリアル・トランスロケーションが促進される。さらに、特に腹部手術の間には、外科手術自体が腸管バリアの破綻をもたらし得る。このトランスロケーションは、敗血症、菌血症及び内毒血症を含む短期及び中期の合併症をもたらす。外科手術の間に放出され得る、腸管内に生息する微生物による感染の結果として、腹膜の炎症である腹膜炎も生じ得る。
本発明は、(a)次亜塩素酸、(b)二価カチオン、(c)リン酸アニオン(phosphate anion)及び(d)水を含む抗微生物(antimicrobial)溶液を提供する。本発明はまた、(i)(a)二価カチオン、(b)リン酸アニオン、(c)pH調整剤及び(d)水を含む混合物を提供する工程、並びに(ii)該混合物に塩素ガスを添加する工程、を含む抗微生物溶液を製造するためのプロセスを提供する。さらに、本発明は、哺乳動物における腹部手術と関連する感染症を治療又は予防する方法であって、(a)次亜塩素酸、(b)二価カチオン、(c)リン酸アニオン及び(d)水を含む抗微生物溶液の有効量を哺乳動物に投与することを含む、方法を提供する。
本発明は、(a)次亜塩素酸、(b)二価カチオン、(c)リン酸アニオン及び(d)水を含むか、本質的にそれらからなるか、又はそれらからなる、抗微生物溶液を提供する。
本実施例は、本発明の一実施態様に従って、抗微生物溶液を調製するためのプロセスを実証する。
本実施例は、本発明の一実施態様に従って、本発明の抗微生物溶液の安定性を実証する。
本実施例は、本発明の抗微生物溶液の抗微生物活性を実証する。
Claims (54)
- (a)次亜塩素酸、
(b)二価カチオン、
(c)リン酸アニオン、及び
(d)水
を含む、抗微生物溶液。 - 溶液が、約10 mg/Lから約500 mg/Lの次亜塩素酸を含む、請求項1に記載の溶液。
- 溶液が、約50 mg/Lから約250 mg/Lの次亜塩素酸を含む、請求項1又は2に記載の溶液。
- 二価カチオンが、マグネシウム、カルシウム又はそれらの組み合わせである、請求項1〜3のいずれか一項に記載の溶液。
- 二価カチオンが約20 mg/Lから約250 mg/Lの量で存在する、請求項4に記載の溶液。
- 二価カチオンがマグネシウムである、請求項4又は5に記載の溶液。
- マグネシウムが硫酸マグネシウムにより提供される、請求項6に記載の溶液。
- 二価カチオンがカルシウムである、請求項4又は5に記載の溶液。
- カルシウムが硫酸カルシウムにより提供される、請求項7に記載の溶液。
- リン酸アニオンがリン酸二水素ナトリウムにより提供される、請求項1〜8のいずれか一項に記載の溶液。
- リン酸二水素ナトリウムが、PO4 2-と式化されるリン酸アニオンを約200 mg/Lから約1000 mg/L提供するのに十分な量で存在する、請求項10に記載の溶液。
- 溶液が、約10 mg/Lから約400 mg/Lの塩化物イオンを更に含む、請求項1〜11のいずれか一項に記載の溶液。
- 溶液が、約3から約7のpHを有する、請求項1〜12のいずれか一項に記載の溶液。
- 溶液が、約4.5から約5.5のpHを有する、請求項13に記載の溶液。
- 溶液が、
(a)約10 mg/Lから約500 mg/Lの次亜塩素酸、
(b)約20 mg/Lから約250 mg/Lのマグネシウムを提供するのに十分な量の硫酸マグネシウム、
(c)PO4 2-と式化されるリン酸アニオンを約200 mg/Lから約1000 mg/L提供するのに十分な量で存在するリン酸二水素ナトリウム、
(d)約20 mg/Lから約100 mg/Lの塩化物イオン、及び
(e)水
を含み、ここで、該溶液が約3から約7のpHを有する、請求項1〜13のいずれか一項に記載の溶液。 - 溶液が、約4.5から約5.5のpHを有する、請求項15に記載の溶液。
- 請求項1〜16のいずれか一項に記載の溶液、及び医薬上許容される担体を含む、医薬組成物。
- 請求項1〜16のいずれか一項に記載の溶液又は請求項17に記載の組成物を含む、密封容器。
- 請求項1〜16のいずれか一項に記載の溶液又は請求項17に記載の組成物、及びそれを使用するための説明書を含む、キット。
- (i)(a)二価カチオン、(b)リン酸アニオン、(c)pH調整剤及び(d)水を含む混合物を提供する工程、並びに
(ii)該混合物に塩素ガスを添加する工程
を含む、抗微生物溶液を製造するためのプロセス。 - プロセスが、約3から約7のpHを有する溶液を製造する、請求項20に記載のプロセス。
- プロセスが、約4.5から約5.5のpHを有する溶液を製造する、請求項21に記載のプロセス。
- プロセスが、約10 mg/Lから約500 mg/Lの量の次亜塩素酸を含む溶液を製造する、請求項20に記載のプロセス。
- プロセスが、約50 mg/Lから約250 mg/Lの量の次亜塩素酸を含む溶液を製造する、請求項23に記載のプロセス。
- 二価カチオンが、マグネシウム、カルシウム又はそれらの組み合わせである、請求項20〜24のいずれか一項に記載のプロセス。
- 二価カチオンが約20 mg/Lから約250 mg/Lの量で存在する、請求項25に記載のプロセス。
- 二価カチオンがマグネシウムである、請求項25又は26に記載のプロセス。
- マグネシウムが硫酸マグネシウムにより提供される、請求項27に記載のプロセス。
- 二価カチオンがカルシウムである、請求項25又は26に記載のプロセス。
- カルシウムが硫酸カルシウムにより提供される、請求項29に記載のプロセス。
- リン酸アニオンがリン酸二水素ナトリウムにより提供される、請求項20〜30のいずれか一項に記載のプロセス。
- リン酸二水素ナトリウムが、PO4 2-と式化されるリン酸アニオンを約200 mg/Lから約1000 mg/L提供するのに十分な量で存在する、請求項31に記載のプロセス。
- 溶液が、約20 mg/Lから約100 mg/Lの塩化物イオンを更に含む、請求項20〜32のいずれか一項に記載のプロセス。
- 塩素ガスをバッファー溶液中にバブリングさせる、請求項20に記載のプロセス。
- プロセスが連続的である、請求項20に記載のプロセス。
- (i)次亜塩素酸及び水を含む混合物を提供する工程、並びに
(ii)該混合物に、(a)二価カチオン、(b)リン酸アニオン及び(c)pH調整剤を添加する工程
を含む、抗微生物溶液を製造するためのプロセス。 - 次亜塩素酸が電気化学的に生成される、請求項36に記載のプロセス。
- プロセスが、約3から約7のpHを有する溶液を製造する、請求項36又は37に記載のプロセス。
- プロセスが、約4.5から約5.5のpHを有する溶液を製造する、請求項38に記載のプロセス。
- プロセスが、約10 mg/Lから約500 mg/Lの量の次亜塩素酸を含む溶液を製造する、請求項36に記載のプロセス。
- プロセスが、約50 mg/Lから約250 mg/Lの量の次亜塩素酸を含む溶液を製造する、請求項40に記載のプロセス。
- 二価カチオンが、マグネシウム、カルシウム又はそれらの組み合わせである、請求項36〜41のいずれか一項に記載のプロセス。
- 二価カチオンが約20 mg/Lから約250 mg/Lの量で存在する、請求項42に記載のプロセス。
- 二価カチオンがマグネシウムである、請求項42又は43に記載のプロセス。
- マグネシウムが硫酸マグネシウムにより提供される、請求項44に記載のプロセス。
- 二価カチオンがカルシウムである、請求項42又は43に記載のプロセス。
- カルシウムが硫酸カルシウムにより提供される、請求項46に記載のプロセス。
- リン酸アニオンがリン酸二水素ナトリウムにより提供される、請求項36〜47のいずれか一項に記載のプロセス。
- リン酸二水素ナトリウムが、PO4 2-と式化されるリン酸アニオンを約200 mg/Lから約1000 mg/L提供するのに十分な量で存在する、請求項48に記載のプロセス。
- 溶液が、約20 mg/Lから約100 mg/Lの塩化物イオンを更に含む、請求項36〜49のいずれか一項に記載のプロセス。
- 哺乳動物における腹部手術と関連する感染症を治療又は予防する方法であって、請求項1〜16のいずれか一項に記載の溶液又は請求項17に記載の医薬組成物の有効量を哺乳動物に投与することを含む、方法。
- 手術が、鼠径ヘルニア手術、試験開腹術、虫垂切除術又はラパロスコピーである、請求項51に記載の方法。
- 溶液が、洗浄により腹腔に投与される、請求項51又は52に記載の方法。
- 感染症が、メチシリン耐性黄色ブドウ球菌(methicilln-resistant S. aureus)、大腸菌(E. coli)、緑膿菌(P. aeruginosa)、バンコマイシン耐性腸球菌(Vancomycin-resistant Enterococcus)、プロテウス・ミラビリス(P. mirabilis)、セラチア・マルセッセンス(S. marcescens)及びカンジダ・アルビカンス(C. albicans)から選択される生物により引き起こされる、請求項51〜53のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361826382P | 2013-05-22 | 2013-05-22 | |
US61/826,382 | 2013-05-22 | ||
PCT/US2014/039202 WO2014190184A1 (en) | 2013-05-22 | 2014-05-22 | Stabilized hypochlorous acid solution and use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016521684A true JP2016521684A (ja) | 2016-07-25 |
JP2016521684A5 JP2016521684A5 (ja) | 2017-06-29 |
JP6416227B2 JP6416227B2 (ja) | 2018-10-31 |
Family
ID=51934166
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016515094A Expired - Fee Related JP6416227B2 (ja) | 2013-05-22 | 2014-05-22 | 安定化次亜塩素酸溶液及びその使用 |
Country Status (6)
Country | Link |
---|---|
US (2) | US9918477B2 (ja) |
EP (1) | EP2999341B1 (ja) |
JP (1) | JP6416227B2 (ja) |
CA (1) | CA2913137A1 (ja) |
MX (1) | MX2015016057A (ja) |
WO (1) | WO2014190184A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070196434A1 (en) | 2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of preventing or treating sinusitis with oxidative reductive potential water solution |
JP6416227B2 (ja) * | 2013-05-22 | 2018-10-31 | ソノマ ファーマシューティカルズ、インコーポレイテッド | 安定化次亜塩素酸溶液及びその使用 |
WO2019006217A1 (en) | 2017-06-28 | 2019-01-03 | Collidion, Inc. | COMPOSITIONS, METHODS AND USES FOR CLEANING, DISINFECTION AND / OR STERILIZATION |
KR20200123421A (ko) | 2018-01-14 | 2020-10-29 | 콜리디온, 인코포레이티드 | 세척, 소독, 멸균 및/또는 치료를 위한 조성물, 키트, 방법 및 용도 |
LU101842B1 (en) | 2020-06-08 | 2021-12-08 | Arnaud Mainnemare | Pharmaceutical Composition for treating or preventing lesions and infections in a mammal |
US11097945B1 (en) | 2020-11-04 | 2021-08-24 | Cougar Creek Electrolysed Water, Llc | Methods and systems for production of an aqueous hypochlorous acid solution |
IT202000028082A1 (it) | 2020-11-23 | 2022-05-23 | Md Italy Srl | Composizione, preparazione ed impiego di una miscela a base di bromo per l’igiene perioculare, il trattamento e la prevenzione delle blefariti |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002249407A (ja) * | 2001-02-22 | 2002-09-06 | Tsukasa Denshi Kk | 殺菌消毒剤 |
JP2012530142A (ja) * | 2009-06-15 | 2012-11-29 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 次亜塩素酸を含有する溶液及びその使用方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100737951B1 (ko) * | 1999-12-10 | 2007-07-13 | 가오가부시끼가이샤 | 살균제 조성물 |
US20050139808A1 (en) | 2003-12-30 | 2005-06-30 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and process for producing same |
EP3205358A1 (en) | 2003-12-30 | 2017-08-16 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and method of using the same |
US20050196462A1 (en) | 2003-12-30 | 2005-09-08 | Oculus Innovative Sciences, Inc. | Topical formulation containing oxidative reductive potential water solution and method for using same |
US9168318B2 (en) | 2003-12-30 | 2015-10-27 | Oculus Innovative Sciences, Inc. | Oxidative reductive potential water solution and methods of using the same |
CN101163491B (zh) | 2005-03-23 | 2017-04-19 | 奥古露丝创新科学公司 | 利用氧化还原电位水溶液治疗皮肤溃疡的方法 |
KR101532778B1 (ko) | 2005-03-23 | 2015-06-30 | 오클루스 이노바티브 사이언시즈 인코포레이티드 | 산화 환원 전위 수용액을 사용한 2도 및 3도 화상의 치료방법 |
WO2006119300A2 (en) | 2005-05-02 | 2006-11-09 | Oculus Innovative Sciences, Inc. | Method of using oxidative reductive potential water solution in dental applications |
US20070196434A1 (en) | 2006-01-20 | 2007-08-23 | Oculus Innovative Sciences, Inc. | Methods of preventing or treating sinusitis with oxidative reductive potential water solution |
CN101932330B (zh) | 2007-03-13 | 2015-01-14 | 奥古露丝创新科学公司 | 包括一氧化二氯的抗微生物溶液及其制备和使用方法 |
CA2769644C (en) | 2009-07-30 | 2019-11-12 | Oculus Innovative Sciences, Inc. | Hydrogel formulation comprising oxidative reductive potential water |
GB2488838A (en) | 2011-03-11 | 2012-09-12 | Biomimetics Health Ind Ltd | A stable antimicrobial aqueous hypochlorous acid solution |
JP6416227B2 (ja) | 2013-05-22 | 2018-10-31 | ソノマ ファーマシューティカルズ、インコーポレイテッド | 安定化次亜塩素酸溶液及びその使用 |
-
2014
- 2014-05-22 JP JP2016515094A patent/JP6416227B2/ja not_active Expired - Fee Related
- 2014-05-22 CA CA2913137A patent/CA2913137A1/en not_active Abandoned
- 2014-05-22 WO PCT/US2014/039202 patent/WO2014190184A1/en active Application Filing
- 2014-05-22 EP EP14801652.0A patent/EP2999341B1/en not_active Not-in-force
- 2014-05-22 MX MX2015016057A patent/MX2015016057A/es active IP Right Grant
- 2014-05-22 US US14/893,448 patent/US9918477B2/en active Active
-
2018
- 2018-03-20 US US15/926,927 patent/US10412969B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002249407A (ja) * | 2001-02-22 | 2002-09-06 | Tsukasa Denshi Kk | 殺菌消毒剤 |
JP2012530142A (ja) * | 2009-06-15 | 2012-11-29 | オキュラス イノヴェイティヴ サイエンシズ、インコーポレイテッド | 次亜塩素酸を含有する溶液及びその使用方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2999341A1 (en) | 2016-03-30 |
WO2014190184A1 (en) | 2014-11-27 |
US10412969B2 (en) | 2019-09-17 |
US20160120183A1 (en) | 2016-05-05 |
US9918477B2 (en) | 2018-03-20 |
US20180206502A1 (en) | 2018-07-26 |
JP6416227B2 (ja) | 2018-10-31 |
MX2015016057A (es) | 2016-03-21 |
EP2999341A4 (en) | 2016-11-02 |
EP2999341B1 (en) | 2018-11-28 |
CA2913137A1 (en) | 2014-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6416227B2 (ja) | 安定化次亜塩素酸溶液及びその使用 | |
JP6033082B2 (ja) | 次亜塩素酸を含有する溶液及びその使用方法 | |
CN103796515B (zh) | 稳定的次卤酸溶液 | |
KR101569134B1 (ko) | 일산화 이염소 함유 항균 용액, 그의 제조 방법 및 사용 방법 | |
US7393522B2 (en) | Physiologically balanced, ionized, acidic solution and methodology for use in wound healing | |
CN1289095C (zh) | 生理上平衡的离子化的酸性溶液及其应用于伤口愈合的方法 | |
US6309673B1 (en) | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy | |
CN1678328A (zh) | 生理上平衡的离子化酸性溶液及用于伤口愈合的方法 | |
EP2133083A1 (en) | Therapeutic agent for infectious skin or mucosal disease | |
TW200803931A (en) | System and method for the prevention of bacterial and fungal infections including urinary tract infections (UTI) using N-halogenated amino acids | |
US20090170932A1 (en) | Disinfectant compositions, methods and systems | |
WO2010075477A2 (en) | Methods of treating or preventing biofilm associated infections with free available chlorine water | |
CN116367859A (zh) | 用于降低伤口中生物负荷的方法和组合物 | |
RU2331441C1 (ru) | Гипергазированное и гиперосмотическое антисептическое средство | |
RU2296570C2 (ru) | Способ лечения нагноившихся остаточных полостей печени после эхинококкэктомии | |
RU2809542C1 (ru) | Способ сопроводительной терапии при хирургическом лечении патологических и застарелых переломов | |
JP2020502249A (ja) | バイオフィルムを処置するための酢酸および次亜塩素酸を含む組成物および方法 | |
KR20220154113A (ko) | 세정, 소독, 살균 및/또는 처리를 위한 조성물, 키트, 방법 및 용도 | |
TWI532494B (zh) | 降低可利斯汀(colistin)注射劑副作用之方法 | |
MX2010009435A (es) | Solucion electrolizada de super oxidacion con ph neutro y uso de la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170517 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170517 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180508 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180807 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180904 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181003 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6416227 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |